Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
Roy M FleischmannJerzy SwierkotSara K PennPatrick DurezLouis BessetteXianwei BuNasser KhanYihan LiCharles G PeterfyYoshiya TanakaEduardo MyslerPublished in: RMD open (2024)
NCT02629159.